Skip to main content
OpenTrials

Clinical trial condition

Adenocarcinoma

Explore clinical trials studying Adenocarcinoma. Study availability and eligibility vary by location and protocol.

5,030 public trials 1,171 recruiting studies
Refine in advanced search Browse all conditions

Adenocarcinoma trial results

Active, Not Recruiting

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

NCT04626479

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • University of California at San Francisco ( Site 1008) San Francisco, California, United States
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 1011) New Haven, Connecticut, United States
  • University of Chicago ( Site 1013) Chicago, Illinois, United States
  • University of Iowa ( Site 1012) Iowa City, Iowa, United States
View all 55 locations
View Trial Details
Active, Not Recruiting

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

NCT04194775

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • Southern California Research Center Coronado, California, United States
  • Inland Empire Liver Foundation Rialto, California, United States
  • Mercy Medical Center Baltimore, Maryland, United States
  • UMass Memorial Medical Center Worcester, Massachusetts, United States
View all 74 locations
View Trial Details
Active, Not Recruiting

Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.

NCT03647878

Conditions
Adenocarcinoma, Advanced Renal Cell Carcinoma, Carcinoma, +15 more
Locations
  • Landeskrankenhaus Hochsteiermark Leoben, Austria
  • Kepler Universitätsklinikum GmbH Linz, Austria
  • Uniklinikum Salzburg Salzburg, Austria
  • Salzkammergutklinikum Vöcklabruck Vöcklabruck, Austria
View all 82 locations
View Trial Details
Active, Not Recruiting

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT05891171

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Cancer, +64 more
Locations
  • Research Site Phoenix, Arizona, United States
  • Research Site Jacksonville, Florida, United States
  • Research Site Lake City, Florida, United States
  • Research Site Hinsdale, Illinois, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

NCT03793166

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +27 more
Locations
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 860 locations
View Trial Details
Active, Not Recruiting

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

NCT02772003

Conditions
Adenocarcinoma, Blood-Borne Infections, Carcinoma, +25 more
Locations
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
  • Case Western Reserve University Cleveland, Ohio, United States
  • Temple University Hospital Philadelphia, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

NCT06506955

Conditions
Adenocarcinoma, Advanced/Metastatic Cancer, Carcinoma, +8 more
Locations
  • University of California, San Francisco (UCSF) San Francisco, California, United States
  • Institut Paoli-Calmettes Marseille, France
  • Institut De Cancerologie Strasbourg Strasbourg, France
  • Severance Hospital Seoul, South Korea
View Trial Details
Active, Not Recruiting

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT03298451

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Orange, California, United States
  • Research Site San Francisco, California, United States
  • Research Site Washington D.C., District of Columbia, United States
View all 160 locations
View Trial Details
Active, Not Recruiting

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

NCT02595424

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Islet Cell, +19 more
Locations
  • Kingman Regional Medical Center Kingman, Arizona, United States
  • Cancer Center at Saint Joseph's Phoenix, Arizona, United States
  • Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
  • CHI Saint Vincent Cancer Center Hot Springs Hot Springs, Arkansas, United States
View all 673 locations
View Trial Details

Related conditions